Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article Free
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Beck, P. L.
space
  arrow  Lee, S. S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF REPORT

Chronic Active Hepatitis Associated with Trazodone Therapy

right arrow Paul L. Beck; Ronald J. Bridges; Douglas J. Demetrick; James K. Kelly; and Samuel S. Lee

15 May 1993 | Volume 118 Issue 10 | Pages 791-792

Trazodone is a widely used nontricyclic antidepressant agent that has been commercially available in North America for more than 10 years. There have been three previously reported cases of trazodone-induced hepatic injury, all of which resolved within 4 to 24 weeks after cessation of the drug. We report the first documented case of trazodone-induced chronic active hepatitis. The patient developed jaundice 8 months after beginning therapy with the drug. Her liver enzymes were markedly elevated, and mild portal hypertension was present at transjugular liver biopsy. The biopsy specimen showed a pattern consistent with chronic active hepatitis. Investigations of other possible causes of chronic active hepatitis were negative, and serum transaminase enzyme levels rapidly returned to normal after withdrawal of trazodone. We suggest that physicians be alert to the possibility of hepatic injury in patients receiving trazodone.

Author and Article Information
space

From the University of Calgary, Calgary, Alberta.
Requests for Reprints: S. S. Lee, MD, 3330 University Drive Northwest, Calgary, Alberta T2N 4N1, Canada.




This article has been cited by other articles:


Home page
Toxicol SciHome page
J. A. Dykens, J. D. Jamieson, L. D. Marroquin, S. Nadanaciva, J. J. Xu, M. C. Dunn, A. R. Smith, and Y. Will
In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone
Toxicol. Sci., June 1, 2008; 103(2): 335 - 345.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
B. Wen, L. Ma, A. D. Rodrigues, and M. Zhu
Detection of Novel Reactive Metabolites of Trazodone: Evidence for CYP2D6-Mediated Bioactivation of m-Chlorophenylpiperazine
Drug Metab. Dispos., May 1, 2008; 36(5): 841 - 850.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
K. P DeSanty and C. M Amabile
Antidepressant-Induced Liver Injury
Ann. Pharmacother., July 1, 2007; 41(7): 1201 - 1211.
[Abstract] [Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 1993 by the American College of Physicians.